Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

Journal of the National Cancer Institute

Volumn 88, Issue 21, 1996, Pages 1529-1542

  Fisher, Bernard ^a   Dignam, James ^b   Bryant, John ^b   DeCillis, Arthur ^b   Wickerham, D Lawrence ^b   Wolmark, Norman ^b   Costantino, Joseph ^b   Redmond, Carol ^b   Fisher, Edwin R ^b   Bowman, David M ^b   Deschênes, Luc ^b   Dimitrov, Nikolay V ^b   Margolese, Richard G ^b   Robidoux, André ^b   Shibata, Henry ^b   Terz, Jose ^b   Paterson, A H G ^b   Feldman, Merrill I ^b   Farrar, William ^b   Evans, James ^b   Lickley, H Lavina ^b   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; SECOND CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTORS, ESTROGEN; RISK; TAMOXIFEN; TIME FACTORS;

EID: 10344238569     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.21.1529     Document Type: Article

References (39)

1. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
2. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Monogr Natl Cancer Inst 1992;11:105-16.
3. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305:1-6.
4. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979;35:183-97.
5. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1972; 58:403-17.
6. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
7. Fisher B, Wolmark N, Fisher ER, Deutsch M. Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations. World J Surg 1985;9:692-8.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
10. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993;88:400-9.
11. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
12. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials 1984;5:348-61.
13. NSABP halts B-14 trial: no benefit seen beyond 5 years of tamoxifen use [news]. J Natl Cancer Inst 1995;87:1829.
14. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987;2:171-5.
15. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995;35: 195-211.
16. Osborne CK. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 1993;47: 83-9.
17. Johnston SR, Dowsett M, Smith IE. Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 1992;3:503-11.
18. Tripathy D. How long should adjuvant tamoxifen be continued? Oncology (Huntingt) 1994;8:25-33; discussion 33, 37-8.
19. Wolf DM, Jordan VC, William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat 1993;27:27-40.
20. Wiseman H. Tamoxifen: molecular basis of use in cancer treatment and prevention. Chichester, West Sussex (U.K.): John Wiley & Sons. 1994:96-105.
21. Canney PA, Griffiths T, Latief TN, Priestman TJ. Clinical significance of tamoxifen withdrawal response [letter]. Lancet 1987;1:36.
22. Howell A, Dodwell DJ, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992;3:611-7.
23. Horwitz KB. Can hormone resistant breast cancer cells be inappropriately stimulated by tamoxifen? Ann N Y Acad Sci 1993;684:63-74.
24. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-15, 71-85.
25. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
26. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br J Cancer 1988;57:608-11.
27. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406.
28. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-80.
29. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993;14:315-7.
30. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993;53:3919-24.
31. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
32. Jordan VC. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. Ann Oncol 1995;6:29-34.
33. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J , Natl Cancer Inst 1995;87:645-51.
34. Fisher B. Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 1996;14:1027-39.
35. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin , WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
36. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-7.
37. Ryden S, Ferno M, Moller T, Aspegren K, Bergljung L, Killander D, et al. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 1992;31:271-4.
38. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. Monogr Natl Cancer Inst 1992;11:121-5.
39. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Monogr Natl Cancer Inst 1992;11:117-20.